Meiyu Fang

机构：Tianjin University, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Cancer Hospital of Chinese Academy of Medical Sciences, University of Chinese Academy of Sciences, Hangzhou Cancer Hospital, Tianjin Medical University

发表论文 106 篇 · 总被引 1690 次 · h-index 20

代表论文

• Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006): a multicentre, open-label, single-arm, phase 2 trial (2023 · EClinicalMedicine · 被引 34)
• Finotonlimab with chemotherapy in recurrent or metastatic head and neck cancer: a randomized phase 3 trial (2024 · Nature Medicine · 被引 32)
• ARTEMIS-002: Phase 2 study of HS-20093 in patients with relapsed or refractory osteosarcoma. (2024 · Journal of Clinical Oncology · 被引 18)
• Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study (2024 · Therapeutic Advances in Medical Oncology · 被引 14)
• RETRACTED: Ultra-sensitive detection of melanoma NRAS mutant ctDNA based on programmable endonucleases (2025 · Cancer Genetics · 被引 9)
• Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis (2025 · Clinical and Translational Medicine · 被引 9)